Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study.


Journal

Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 15 01 2018
accepted: 19 06 2018
pubmed: 29 6 2018
medline: 30 5 2019
entrez: 29 6 2018
Statut: ppublish

Résumé

Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the pre-dialysis period has not been fully examined. We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study to identify factors that are associated with increased LVMI in patients with stage 3-5 CKD. We analyzed the baseline characteristics in 1088 participants (male 63.8%, female 36.2%). Diabetes mellitus was the underlying disease in 41.7% of the patients, and mean age was 61.8 ± 11.1 years. LVH was detected in 23.4% of the patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease [odds ratio (OR) 2.364; 95% confidence interval ([CI) 1.463-3.822; P = 0.0004], body mass index (OR 1.108; 95% CI 1.046-1.173; P = 0.0005), systolic blood pressure (OR 1.173; 95% CI 1.005-1.369; P = 0.0433), urinary albumin (OR 1.425; 95% CI 1.028-1.974; P = 0.0333), and serum total cholesterol level (OR 0.994; 95% CI 0.989-0.999; P = 0.0174). The cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.

Sections du résumé

BACKGROUND BACKGROUND
Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the pre-dialysis period has not been fully examined.
METHODS METHODS
We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study to identify factors that are associated with increased LVMI in patients with stage 3-5 CKD.
RESULTS RESULTS
We analyzed the baseline characteristics in 1088 participants (male 63.8%, female 36.2%). Diabetes mellitus was the underlying disease in 41.7% of the patients, and mean age was 61.8 ± 11.1 years. LVH was detected in 23.4% of the patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease [odds ratio (OR) 2.364; 95% confidence interval ([CI) 1.463-3.822; P = 0.0004], body mass index (OR 1.108; 95% CI 1.046-1.173; P = 0.0005), systolic blood pressure (OR 1.173; 95% CI 1.005-1.369; P = 0.0433), urinary albumin (OR 1.425; 95% CI 1.028-1.974; P = 0.0333), and serum total cholesterol level (OR 0.994; 95% CI 0.989-0.999; P = 0.0174).
CONCLUSION CONCLUSIONS
The cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.

Identifiants

pubmed: 29951723
doi: 10.1007/s10157-018-1605-z
pii: 10.1007/s10157-018-1605-z
pmc: PMC6344393
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

85-98

Commentaires et corrections

Type : ErratumIn

Références

Am J Kidney Dis. 1999 Jul;34(1):125-34
pubmed: 10401026
Nephrol Dial Transplant. 2001 Mar;16(3):459-68
pubmed: 11239016
Am J Med Sci. 2001 Apr;321(4):225-36
pubmed: 11307864
Nephrol Dial Transplant. 2001;16 Suppl 2:3-6
pubmed: 11369841
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
pubmed: 11904577
J Am Soc Nephrol. 2003 May;14(5):1330-5
pubmed: 12707402
J Am Soc Nephrol. 2004 Jun;15(6):1640-7
pubmed: 15153576
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
Kidney Int. 2005 Jul;68(1):228-36
pubmed: 15954912
Am J Kidney Dis. 2005 Aug;46(2):320-7
pubmed: 16112052
Kidney Int. 2006 Apr;69(7):1264-71
pubmed: 16501489
Eur Heart J. 2006 May;27(10):1245-50
pubmed: 16611670
Clin Exp Nephrol. 2007 Jun;11(2):156-163
pubmed: 17593516
Hypertens Res. 2008 Jun;31(6):1101-7
pubmed: 18716357
Nephrol Dial Transplant. 2009 May;24(5):1506-23
pubmed: 19001560
J Hypertens. 2009 Mar;27(3):633-41
pubmed: 19262231
Circulation. 2009 Apr 14;119(14):1892-8
pubmed: 19332464
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Clin Exp Nephrol. 2009 Dec;13(6):621-30
pubmed: 19513802
BMJ. 2009 Jun 29;338:b2392
pubmed: 19564178
J Hypertens. 2010 May;28(5):1065-73
pubmed: 20411600
Kidney Int. 2010 Jul;78(1):14-8
pubmed: 20445499
Clin Exp Nephrol. 2010 Dec;14(6):558-70
pubmed: 20700621
Clin Exp Nephrol. 2011 Apr;15(2):187-94
pubmed: 21104421
PLoS One. 2011 Jan 31;6(1):e16630
pubmed: 21304952
J Am Soc Nephrol. 2012 Oct;23(10):1725-34
pubmed: 22935481
J Hypertens. 2012 Dec;30(12):2378-86
pubmed: 23137952
Eur Heart J Cardiovasc Imaging. 2014 Jan;15(1):56-61
pubmed: 23811493
Hypertens Res. 2014 Mar;37(3):246-52
pubmed: 24089265
Clin Physiol Funct Imaging. 2015 May;35(3):223-30
pubmed: 24750894
Lancet Diabetes Endocrinol. 2015 Jul;3(7):514-25
pubmed: 26028594
Clin J Am Soc Nephrol. 2016 Feb 5;11(2):271-9
pubmed: 26668021
Clin Exp Nephrol. 2017 Jun;21(3):446-456
pubmed: 27412450
Kidney Int. 2017 Jan;91(1):227-234
pubmed: 27884399
Am J Hypertens. 2017 Aug 1;30(8):822-829
pubmed: 28444108
J Am Heart Assoc. 2017 Sep 22;6(9):null
pubmed: 28939714
Am J Cardiol. 1986 Feb 15;57(6):450-8
pubmed: 2936235
Circulation. 1981 Jun;63(6):1391-8
pubmed: 6452972
Am J Kidney Dis. 1996 Mar;27(3):347-54
pubmed: 8604703
Nephrol Dial Transplant. 1997 Apr;12(4):724-8
pubmed: 9141001

Auteurs

Kosaku Nitta (K)

Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, 162-8666, Japan. knitta@twmu.ac.jp.

Satoshi Iimuro (S)

Teikyo Academic Research Center, Teikyo University, Tokyo, Japan.

Enyu Imai (E)

Nakayamadera Imai Clinic, Hyogo, Japan.

Seiichi Matsuo (S)

Department of Nephrology, Nagoya University, Aichi, Japan.

Hirofumi Makino (H)

Okayama University, Okayama, Japan.

Tadao Akizawa (T)

Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Tsuyoshi Watanabe (T)

Japan Organization of Occupational Health and Safety Fukushima Rosai Hospital, Fukushima, Japan.

Yasuo Ohashi (Y)

Department of Integrated Science and Engineering for Sustainable Society, Chuo University, Tokyo, Japan.

Akira Hishida (A)

Yaizu City Hospital, Shizuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH